Medicina
Facultad
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublicaciones en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (176)
2024
-
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study
Journal of Thoracic Oncology, Vol. 19, Núm. 2, pp. 285-296
-
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 180-191
-
Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Clinical Cancer Research, Vol. 30, Núm. 4, pp. 824-835
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke
Frontiers in Neurology, Vol. 14
-
Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: International observational federated study based on electronic health records through the 4CE consortium
PLoS ONE, Vol. 18, Núm. 1 January
-
Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry
Genome Medicine, Vol. 15, Núm. 1
-
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2039-2051
-
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
JTO Clinical and Research Reports, Vol. 4, Núm. 1
-
Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Clinical Cancer Research, Vol. 29, Núm. 21
-
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
Journal of Thoracic Oncology, Vol. 18, Núm. 12, pp. 1731-1742
-
Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change
Journal of Acquired Immune Deficiency Syndromes, Vol. 93, Núm. 1, pp. 42-46
-
Consensus Recommendations for Standardized Data Elements, Scales, and Time Segmentations in Studies of Human Circadian/Diurnal Biology and Stroke
Stroke, Vol. 54, Núm. 7, pp. 1943-1949
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer
Breast, Vol. 67, pp. 94-101
-
First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia
Journal of the Pediatric Infectious Diseases Society, Vol. 12, Núm. 11, pp. 581-585
-
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Journal for immunotherapy of cancer, Vol. 11, Núm. 2
-
Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 4, pp. 680-688
-
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study
British Journal of Cancer, Vol. 128, Núm. 1, pp. 137-147
-
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185